{"entity":{"id":"nct07679360","kind":"trial","name":"A Study of Trastuzumab Rezetecan in Combination With Adebrelimab Versus Investigator's Choice of Therapy in Subjects With Residual Triple Negative Breast Cancer","aka":[],"tldr":"A phase 3 trial of Trastuzumab, Trastuzumab rezetecan, Adebrelimab, Capecitabine and Pembrolizumab in triple-negative breast cancer, run by Suzhou Suncadia Biopharmaceuticals Co., Ltd., now recruiting.","summary":"A Study of Trastuzumab Rezetecan in Combination With Adebrelimab Versus Investigator's Choice of Therapy in Subjects With Residual Triple Negative Breast Cancer is a phase 3 interventional study registered as NCT07679360 by Suzhou Suncadia Biopharmaceuticals Co., Ltd., with 1000 participants planned, started 2026-09-02 and due to reach its primary completion in 2030-12. Interventions recorded: Trastuzumab Rezetecan for Injection, Adebrelimab Injection, Capecitabine tablets and Pembrolizumab injection.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07679360","url":"https://clinicaltrials.gov/study/NCT07679360"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["tnbc"],"sections":[],"technologies":[],"targets":[],"drugs":["trastuzumab","trastuzumab-rezetecan","adebrelimab","capecitabine","pembrolizumab"],"companies":["hengrui"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07679360","phase":"3","setting":"A Phase III, Multicenter, Randomized, Open-Label Parallel-Controlled Study of Trastuzumab Rezetecan (SHR-A1811) in Combination With Adebrelimab (SHR-1316) Versus Investigator's Choice of Therapy in Subjects With Primary Triple Negative Breast Cancer Who Have Residual Invasive Disease Following Neoadjuvant Therapy","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","enrolled":1000,"outcomes":[]},"route":"/trials/nct07679360/","neighbours":{"cancer":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"drug":[{"id":"adebrelimab","kind":"drug","name":"Adebrelimab","route":"/drugs/adebrelimab/"},{"id":"capecitabine","kind":"drug","name":"Capecitabine","route":"/drugs/capecitabine/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"},{"id":"trastuzumab","kind":"drug","name":"Trastuzumab","route":"/drugs/trastuzumab/"},{"id":"trastuzumab-rezetecan","kind":"drug","name":"Trastuzumab rezetecan","route":"/drugs/trastuzumab-rezetecan/"}],"company":[{"id":"hengrui","kind":"company","name":"Jiangsu Hengrui Pharmaceuticals","route":"/companies/hengrui/"}]}}